With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

America's Most Innovative Companies

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

The pharmaceutical and medical equipment company makes products that aid in the treatment of health conditions such as kidney disease and hemophilia.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-282-Baxter-International

This Deerfield, Ill. company makes devices and other products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

World's Most Admired Companies

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fortune Global 500

Sector

Culture rank

Process rank

Product rank

Years on list

Previous rank

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Through its subsidiaries, Baxter provides a portfolio of health care products in the U.S. through three segments: medical products and therapies, health care systems and technologies, and pharmaceuticals. Founded in 1931 with headquarters in Deerfield, Ill., it operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand.

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Baxter International (BAX): Company Profile, Stock Price, News, Rankings

legacy

Baxter International

baxter international

As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like to turn the call over to Mr. Kevin Moran, Vice President, Investor Relations at Baxter International. Mr. Moran, you may begin.

Good morning, and welcome. Today we will discuss Baxter's third quarter results along with our updated financial outlook for the full year 2026. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website. Joining me today are Andrew Hider, President and Chief Executive Officer, and John Rogers, Executive Vice President and Chief Financial Officer. During the call, we will be making forward-looking statements, including comments regarding our updated financial outlook for the full year 2026 and the anticipated drivers of the fourth quarter, the anticipated impact of various regulatory, operational, and quality matters, including ones related to our infusion pump platform and ongoing supply challenges, and commentary regarding the global macroeconomic environment, including tariff impacts and the broader inflationary pressures.

Forward-looking statements involve risks and uncertainties which could cause our actual results to differ materially from our current expectations. Please refer to today's press release, the forward-looking statement slide at the beginning of our investor presentation and our SEC filings for more detail. In addition, please note, on the call all of our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. Non-GAAP financial measures are used to help investors understand Baxter's ongoing business performance. GAAP to non-GAAP reconciliations can be found in the schedules attached to our press release and our earnings presentation. On the call, we will reference organic growth, which excludes the impact of foreign exchange, MSA revenues from Vantive, and impacts associated with business acquisitions or divestitures.

Unless otherwise noted, all financial results on today's call reflect continuing operations and exclude Baxter's former Kidney Care business, which is reported as discontinued operations. Finally, Andrew, John, and I will take questions following the prepared remarks, and we kindly ask that you limit yourself to one question and one brief follow-up so that we can give as many people in the queue an opportunity. With that, I would like to turn the call over to Andrew.

Thank you, Kevin, and good morning, everyone. Before discussing the quarter, I want to welcome John Rogers to Baxter as our new Chief Financial Officer. John joined us on October 1st and has a strong track record of leading multiple complex organizations through transformation and performance improvement. His deep financial and operational experience aligns well with our strategic priorities, and I look forward to partnering with him as we continue to advance our turnaround. Now I will turn to the quarter. Our third quarter performance provides further evidence that our turnaround is gaining traction. We continue to advance our strategic priorities and delivered results ahead of our expectations. As a result, we have greater confidence in the full year and are raising our outlook for both organic sales growth and adjusted earnings per share. As I said last quarter, I am encouraged by the steady progress we are making.

We have a lot of work ahead of us to realize the full potential of Baxter. We are focused on executing in the fourth quarter and finishing the year strong while continuing to improve our say-do ratio and deliver more consistent performance. All of these efforts support our objective to create long-term shareholder value. With that, let me turn to a few highlights from the quarter. Third quarter global sales totaled approximately $3 billion, an increase of 5% on both a reported and organic basis. We saw broad-based growth with every division contributing in both segments growing across the U.S. and international markets. Advanced Surgery, drug compounding, and infusion systems were the largest contributors in the quarter. Adjusted earnings were $0.58 per diluted share. While this exceeded our expectations, it represents an expected year-over-year decline due to the discrete tax benefits recognized in the prior year.

End market demand remained generally steady during the quarter, with continued strength in Advanced Surgery and a healthy order book in Care & Connectivity Solutions, or CCS. We continue to closely monitor the external environment, including macroeconomic uncertainty. We are raising our full-year outlook for organic sales growth to a range of 3%-4%, from 2%-3%. We are also raising the bottom end of our outlook for adjusted earnings per diluted share to $2.05-$2.15, compared with our previous range of $1.95-$2.15. Throughout the year, we have communicated a consistent framework for 2026. Known mechanical headwinds and more difficult comparisons in the first half, followed by improved performance in the second half. Our third quarter results are a meaningful proof point that performance is progressing in line with that framework. Let me now turn to the progress we are making against our three strategic priorities.

Stabilizing the business, strengthening the balance sheet, and embedding continuous improvement across Baxter. Our first priority, stabilizing the business. Across the portfolio, we are seeing more consistent execution and further indicators of improved business performance. For example, in our CCS business, an on-time shipment metric improved 8% year-over-year. Additionally, our Advanced Surgery business improved the quality measure by nearly 20% year-over-year. We also saw improvement related to the supply challenges with a contract manufacturer within injectables and expect a more limited impact going forward. We are encouraged by this progress while recognizing there is more work to do to drive greater consistency across our portfolio and manufacturing operations. To that end, we have made the decision to discontinue production of cephalosporin products, which are currently manufactured at our Round Lake, Illinois, specialty injectable facility.

Importantly, this action is not expected to create a market shortage for these products. By repositioning the facility exclusively for non-ceph production, we will simplify and streamline our operations while supporting supply continuity of the non-ceph portfolio. An additional benefit of this action is that it helps address some of the complexities referenced in the recent FDA warning letter we received related to an inspection conducted at the Round Lake facility earlier this year. We have taken significant steps to strengthen quality systems and operations at the site and across our network, including implementing corrective and preventative actions and other enhancements designed to improve quality and operational performance. Product quality, patient safety, and supply reliability are top priorities, and we are committed to addressing the observations and working closely with the FDA throughout the process.

Our second strategic priority is strengthening the balance sheet, and we have made clear progress in the third quarter. Free cash flow was strong at $448 million in the quarter, bringing our year-to-date free cash flow to over $700 million. We also completed a successful tender offer in September. Another meaningful step towards achieving our near-term net leverage objective. We remain confident in our ability to achieve a net leverage ratio of approximately 3x by year end. Sustaining strong cash generation and further strengthening the balance sheet remain near-term priorities. Over time, a stronger balance sheet will increase flexibility, including the opportunity for additional internal investment, strategic tuck-in acquisitions, and share repurchases while maintaining a disciplined approach to creating shareholder value.

As a reminder, we would assess any potential acquisition using a disciplined framework focused on strategic fit, market assessment, our ability to operate and integrate the asset through Baxter GPS, and expected financial returns. Our cultivation process is ongoing, and our funnel remains strong for future potential additions. Our third strategic priority, embedding continuous improvement across Baxter. Baxter GPS is becoming increasingly integrated into how we operate. Strengthening productivity, execution, discipline, and accountability. Year to date, we have completed more than 700 continuous improvement initiatives across Baxter. These events targeted all value creators. We have more than 200 currently in flight and approximately 350 additional initiatives planned. Let me give you a few recent examples of where our teams are applying Baxter GPS to improve both commercial execution and performance.

In Front Line Care, teams improved blood pressure cuff manufacturing cycle times by more than 10%, expanding production capacity without additional capital investment. In our Advanced Surgery business, we have held events focused on strengthening inventory management and improving cash conversion. Across our global services teams, Baxter GPS is driving measurable improvements in execution and customer service. Through cross-functional collaborations, teams streamlined key fulfillment processes, reducing alternative shipment back orders in certain areas of the business by more than 50%. This results in improved customer service and better inventory management. As I've shared before, no single initiative will define our future. The value of Baxter GPS will come from the accumulation of repeatable improvements that translate into better operating and financial performance over time. Innovation is another important element of our strategy and is essential to sustaining portfolio growth and strengthening Baxter's competitive position.

We are seeing continued adoption and customer interest across several recently launched products. For example, Connex 360 continues to gain traction with customers and contributed to Front Line Care's growth in the quarter. Additionally, the Dynamo Series Smart Stretcher was recently recognized for its user-centric design by the Human Factors and Ergonomics Society. These offerings enhance our portfolio and expand our ability to deliver differentiated solutions to customers. In summary, our third quarter results provide further evidence that Baxter is moving in the right direction. We exceeded our expectations for sales, adjusted earnings, and free cash flow, and increased our full-year outlook. At the same time, we advanced each of our three strategic priorities. As we look ahead, our focus is on building greater consistency in how Baxter operates and performs. That means addressing where we need to further improve and building on what is already working.

Disciplined execution will be key to driving stronger performance and sustainable value for shareholders. I will now turn the call over to John to provide more detail on our third quarter results, including segment-level performance and our updated 2026 guidance. John, over to you.

Thanks, Andrew, and good morning, everyone. I'm genuinely excited to join Baxter in this important stage in the company's turnaround. Over the past few weeks, I've been listening and learning through conversations with Andrew, the leadership team, and colleagues across the organization. I've been particularly impressed by Baxter's essential portfolio, its leading positions across the continuum of care, and in particular, the dedication of our employees. I've also seen Baxter GPS in action and have been impressed by how deeply it is already embedded in the organization. At the same time, I do see meaningful opportunities to sharpen execution, accelerate growth, strengthen cash flow generation, and consequently, create long-term shareholder value. I'm very much looking forward to working alongside Andrew and the leadership team.

With that, I'll walk through the details of Baxter's third quarter financial performance, as well as commentary on our updated outlook for the remainder of 2026. Third quarter 2026 global sales totaled approximately $3 billion and increased 5% on both a reported and organic basis. On the bottom line, adjusted earnings were $0.58 per diluted share, a decrease of 16%. This decline reflects an expected higher effective tax rate as the prior year quarter benefited from discrete tax items. Now I'll walk you through our results by reportable segment. Commentary regarding sales growth will be on an organic basis. Sales in our Medical Products & Therapies segment, or MPT, were $2.1 billion and increased 6% in the quarter. Within MPT, sales of our Infusion Therapies & Platforms division totaled $1.8 billion and increased 4%. Growth was driven by infusion systems, drug compounding, and IV solutions.

This growth was partially offset by lower sales in injectables. Growth in infusion systems was driven by Spectrum IQ and also included contributions from our portfolio of digital solutions and our administration set portfolio. Demand for our drug compounding services remained strong in the quarter and grew 9%, reflecting the value proposition we provide to customers in this space. We continue to see strong demand for these services in the international markets we serve as health systems look for scaled, quality-focused outsource solutions. Performance in the quarter also reflects growth in IV solutions. Now off the new lower baseline level of demand following clinical practice changes in the market. Sales of injectables declined 3%, primarily reflecting price deflation and the impact of manufacturing challenges at our Round Lake facility. As Andrew noted, we have taken significant steps to strengthen quality systems and operations.

As part of these efforts, we are discontinuing production of cephalosporin products at the end of October, but will continue to support customers under contract into 2027. These products are expected to contribute approximately $50 million in sales and $30 million in operating income in 2026. Importantly, this action will simplify our operations and support improved performance at the facility. During the quarter, we recorded $39 million in restructuring costs related to these actions. As a reminder, these restructuring costs are excluded from our non-GAAP earnings. Consistent with the first half of the year, we also saw an impact from supply challenges related to a contract manufacturer. Importantly, as Andrew referenced, we saw improvement within the quarter and expect a more limited impact going forward. Sales in Advanced Surgery totaled $342 million and grew 12%.

Results reflect continued strong demand and increased volumes for our global portfolio of hemostats and sealants. Strong commercial execution across regions and steady procedure volumes. MPT's adjusted operating margin totaled 20.9% for the quarter, increasing 10 basis points compared to the prior year period. Results reflect increased sales volume and benefits from previously implemented enterprise cost actions, partially offset by lower contribution from pricing and the impact of mix, including strong growth in drug compounding, coupled with lower sales of injectables. In our Healthcare Systems & Technologies segment, or HST, sales totaled $806 million and increased 4% in the quarter. Within HST, sales of our Care & Connectivity Solutions, or CCS division, were $498 million and grew 5%. Within CCS, performance was driven by contribution from both Global Surgical Solutions and Patient Support Systems, including continued execution against the U.S. backlog and strength across international markets.

To date, we have not observed any change in U.S. hospital capital spending, and our order book continues to reflect solid demand. Nonetheless, we continue to closely monitor the environment, including the potential impact of inflation and interest rate pressures on hospital capital investment decisions. Sales of our Front Line Care, or FLC division, were $308 million and grew 3%. Performance in the quarter reflects continued strength in connected monitoring, driven primarily by strong demand for Connex 360. Partially offsetting this growth was the impact of planned global product exits previously discussed. HST adjusted operating margin totaled 17.2% for the quarter, increasing 140 basis points. Results reflect the benefits from previously implemented cost actions and increased sales volume, partially offset by the impact of mix. Finally, other sales which solely represent MSA revenue from Vantive totaled $68 million.

As a reminder, these sales are included in our reported growth but are not reflected in our organic growth. Moving through the rest of the third quarter P&L. Adjusted gross margins were 38.3%, a decrease of 110 basis points driven by mix of sales and a lower year-over-year contribution from pricing. Adjusted SG&A totaled $637 million or 21.4% of sales, an improvement of 80 basis points. This reflects the benefits from our implemented cost actions. Adjusted R&D spending totaled $118 million or 4% of sales. Other operating income, which includes TSA income and other Vantive-related reimbursements totaled $48 million in the quarter, in line with the prior year, will be a favorable to our expectations. The favorability was driven by Vantive related expenses and therefore did not contribute to earnings.

As we look ahead to a post TSA environment, we remain focused on reducing the impact of stranded costs and improving our cost structure. Altogether, these factors resulted in an adjusted operating margin of 14.5%, a decrease of 40 basis points. The year-over-year change reflects the impact of mix, including strong growth in drug compounding and Global Surgical Solutions and lower sales in injectables. Results also reflect a low contribution for pricing, partially offset by increased sales volumes. Net interest and other expenses totaled $51 million in the quarter. The adjusted tax rate for the quarter was 18.3%, driven primarily by mix of earnings across jurisdictions. As a reminder, the prior year period benefited from the release of reserves for withholding taxes and other discrete tax benefits. In total, adjusted earnings for the quarter were $0.58 per diluted share.

Before turning to our 2026 outlook, I want to comment on cash flow and liquidity. Third quarter free cash flow totaled $448 million, improving sequentially from the second quarter and bringing our year-to-date total to $705 million. This reflects improved operational performance and disciplined execution across targeted areas of working capital. Results in the quarter also benefited from the timing of certain cash receipts, including the IEEPA tariff refund recognized in the prior quarter and proceeds from a legal settlement. We continue to make progress in improving cash flow generation and strengthening our balance sheet. During the quarter, we completed a $600 million cash tender offer, retiring $854 million of debt and further advancing our deleveraging efforts. In connection with the transaction, we recognized a pretax gain of approximately $253 million related to the early extinguishment of debt. As a reminder, this item is excluded from our non-GAAP earnings.

Reducing leverage remains our top near-term capital allocation priority and the actions we have taken year to date, combining with our operating performance and cash flow generation give us increased confidence in achieving our target of approximately three times net leverage by year end. Turning to our updated outlook for the full year 2026. For the full year, we now expect total sales growth to be 4%-5% on a reported basis. This reflects current foreign exchange rates, which are expected to contribute approximately 100 basis points to top-line growth for the year. In addition, reported sales are expected to include a headwind of approximately $25 million from MSA revenues from Vantive, representing approximately 30 basis points of impact on reported growth. Excluding the impact of FX and MSA revenues, we now expect organic sales growth of 3%-4% for 2026.

This reflects our strong year-to-date performance and our latest expectations as we close out the year. As it relates to the segments. In MPT, we now expect full-year organic sales to grow low to mid-single digits. This reflects stronger year-to-date performance across our businesses, driven by drug compounding and Advanced Surgery. In HST, we continue to expect full-year organic sales to grow low single digits, supported by anticipated contributions from both the CCS and FLC divisions. Turning to our outlook for other P&L line items and key assumptions. TSA income and other Vantive-related reimbursements are now expected to range between $165 million-$175 million. Higher TSA income and other Vantive-related reimbursements are expected to be broadly offset by higher Vantive-related expenses, and therefore are not expected to contribute to earnings. We continue to expect full-year adjusted operating margin of 13%-14%.

We now expect our non-operating expenses, which include net interest and other expense, to total between $245 million-$255 million, reflecting lower interest expense following debt reduction associated with our recent cash tender offer. We continue to anticipate our full-year tax rate to range between 18.5% and 19.5%. We now expect our diluted share count to average approximately 590 million shares for the year.

Given the strong performance year-to-date, we are raising the low end and narrowing our full-year adjusted earnings from $1.95 to $2.15 per diluted share to $2.05 to $2.15 per diluted share. In closing, I am encouraged by both our third quarter results as well as the continued progress we are seeing across the organization, including the growing momentum behind Baxter GPS. As we begin to look forward to 2027, we are encouraged by our progress year-to-date and the actions we have taken to strengthen the business.

We will provide a comprehensive outlook for 2027, including detailed guidance on our fourth quarter earnings call in February. With that, we can now open up the call for Q&A.

Thank you. We will now begin the question-and-answer session. If you have a question, please press star followed by the number one on your touch tone phone. If you wish to remove yourself from the queue, press star one again. If you are using a speakerphone, please lift the handset to ask your question. So that we may be respectful of everyone's time, please limit your comments to one question with one brief follow-up question if necessary. We appreciate everyone's consideration, as we would like to provide as many of you as possible the opportunity to ask a question.

We will pause for a moment while the list is being compiled. I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com. Your first question from the line of Travis Steed with Bank of America. Your question please.

Hey, thanks for the question. I wanted to ask about the warning letter and the product discontinuation. I heard $50 million revenue and $30 million op income in 2026. Maybe just help us understand more what's going on there. Why the decision to discontinue the product, and does this make it harder to grow EPS in 2027 versus 2026, taking into account all the plus and takes on the model? I think it's like a 2% headwind by our math on 2027 on EPS.

Yeah. Hey, good morning, Travis. Let me walk through this and kind of outline the decision here. Look, this reflects our ongoing evaluation of our portfolio and manufacturing operations. By doing this process or walking through this, we're repositioning our Round Lake exclusively for a non-ceph production. This will simplify operations and really support greater supply resiliency. As we look at the remaining portfolio, it enables us to continue to drive that portfolio for the future. Additional benefit is, as we look at this, by reducing this complexity, it does help address some of the issues referenced in the warning letter.

While we do see certainly some areas that the team is looking to offset with the reduction of the ceph production line, it is an area that is allowing us and enabling us to streamline our approach, our process, and will enable us to really reduce complexity at this specific facility.

Okay. I don't know if there was anything on 2027. I also wanted to ask about M&A. It seems like there's talk about M&A a little bit. I'm just curious if you could kind of outline the areas you're interested in, the size of deals you're willing to do, and how you think about the ability for deals to be dilutive versus accretive to earnings.

Let me walk this a little bit. First, look, we're pleased with our free cash flow performance, and that really puts us in the ability to start this conversation. As a reminder, we reiterated our approach to be approximately 3x by year-end. Which was our target and alignment, which enables us to move to that next stage. When we look, and I outlined this in my prepared remarks, but as a reminder, when we look at the criteria and our disciplined approach for M&A, it's going to be under four areas. First, the strategic rationales. Oftentimes we're looking for technology, we're looking for geographic expansion. We're looking for areas that we can penetrate and bring the full breadth of Baxter. Number two, the specific market areas to enable our ability to drive expansion.

We're going to look at areas that we view over a long period of time are going to continue to align with the future of Baxter. Number three, how we're going to integrate and operate the asset. What do I mean by that? We look at management teams. We look at the ability to deploy Baxter leaders in. We look at GPS enablement and how we can support the business to outperform, to drive expansion in this market. Then lastly, and this gets to really the heart of the question, is around financial return. Of course, we're going to look at things like ROIC. We're going to look at how earnings are going to perform over the period of time and margin profile and other things also like recurring revenue. There are many areas we look at for potential additions.

I did also reference around how we view tuck-ins for this next phase, and that means that we like our position in many areas, and tuck-ins could be a natural progression. Additionally, our funnels are growing. We have a mantra, ABC, always be cultivating, and our teams are cultivating key targets. Just to wrap this a little bit in a bow, we've also looked at our business and said there's three major buckets. There's the invest and grow and areas we want to continue to support on growth, both organically and inorganically. For example, we like the cardiac monitoring space. We like the Advanced Surgery space. We like key areas across our portfolio that are going to enable us to really drive and support that longer-term growth profile. Then there's a sustain, and then there's also some areas we want to fix and improve.

This is, I would say, an evolution of our approach and process, and it is back to our say-do ratio. We need to get to the approximately 3x times, and once we do that, we can really start to look at the next phase in this journey.

Your next question from the line of Larry Biegelsen of Wells Fargo. Your question, please.

Good morning. Thanks for taking the question. Congrats on another nice quarter here, Andrew. John, you officially joined Baxter just a few weeks ago. Where do you see the biggest opportunities at Baxter? It sounds like you played a big role in the initiatives to improve margins, cash flow, et cetera, at your prior company. Do you run a similar playbook here at Baxter? Lastly, just talk about your approach to guidance, and I will leave it at that, thanks.

Morning, Larry. Look, in terms of what I am going to be focused on in the coming weeks and months, I think first and foremost, coming up to speed with the business, really understanding the business. Obviously, as you said, I have a medtech background, but this is very much a new product set for me. So I want to spend a lot of time with the business, with the management teams out there in the field, really getting up to speed and understanding what makes this business tick. I think in terms of the areas of focus, you have touched upon some of those already. One area, for example, is looking at our margin mix, some of the actions that we need to take and we are taking to drive improvement in that area.

Also, I think building on the great progress to date in driving both operational and functional efficiencies and how we continue to build a pipeline of medium to long-term and very sustainable efficiencies to help offset some of the inflationary pressures that we are seeing. I think thirdly, thinking about how we go about sharpening our capital allocation policy. As the Q3 results demonstrate, and Andrew has just talked about, we are really starting now to generate free cash flow, and the balance sheet is starting to de-gear very nicely. Andrew has already mentioned, of course, the opportunity for M&A, and that, of course, sits alongside other opportunities to reinvest back into our business to drive our organic growth, whether that be R&D or investment in our manufacturing sites, as well, of course, as the possibility for opportunistic share buybacks.

One thing that Andrew and I will be working on over the coming weeks and months is how we hone our capital allocation policy. There will be more to come in that regard. So those would be the sort of the key areas I suspect I will focus on over the coming weeks and months. In terms of the approach to guidance is the question you asked about. Yeah, as we said on the call, we are not going to set out our guidance for 2027 today. We will leave that to the usual timing of our Q4 earnings in February.

That said, of course, there are a number of moving parts or dynamics that I am sure you should consider. First, of course, is inflationary pressures, and we do see those stepping up in 2027 to a degree due to the cap and roll that we talked about previously. But we have actually done a great job in 2026 in offsetting those, and we have line of sight to further saving opportunities in 2027. So we will be looking to mitigate the impact of those inflationary pressures. We then have tariffs, of course. We will not get the same refund benefit in 2027 that we saw in 2026, and we are still, of course, awaiting clarity on Section 232. We should get that sometime in the fourth quarter, so we will have to see the net impact of tariffs going into 2027.

We also expect the TSA services related to Vantive to conclude by the end of January 2027. The consequent headwind that that delivers will depend on how quickly we can take out the stranded costs over the course of the year. Of course, some costs will be very much marginal costs, and they will come out immediately. There will be other costs which are more fixed in nature, and they will take a little bit longer to come out, so we will have to work through that detail.

We are also going to expect an impact from planned product exits, particularly in our FLC portfolio that we have mentioned previously, and we talked on the call today about the ceph products, and we said that contributed $50 million of top line and $30 million of operating income in 2026. To the earlier question, I would not necessarily flow all of that through.

There will be some mitigating factors with how we roll through inventory and some alternative products that we can offset there. But that will be overall a net headwind. We have also called out the sales mix, and I talked about that is an area that really want to focus on as we continue to evaluate the underlying trajectory of the various businesses like drug compounding, injectables. Look, I am three weeks into the role. Obviously, I understand why there is going to be a lot of focus on 2027 right now, but I am going to need a little bit of time just to thoroughly evaluate all these different moving dynamics. We will, of course, come back to this in much more detail when we set out our detailed guidance at our Q4 earnings call in February of 2027.

All right. Thank you for the comprehensive answer and good luck in the new role.

Your next question from the line of Vijay Kumar of Evercore ISI. Your question, please.

Hi, Andrew. Good morning, and thank you for taking my question. John, congrats and welcome. Andrew, maybe my first one for you, is the implied guidance here for Q4 around mid-single, similar to Q3? If that's the case, you had three straight quarters of mid-singles top line performance, how do you think about the sustainability up to 5%? What gets better? What gets worse for FY 2027?

Hey, Vijay. This is Kevin. I think it's important context to think about all year we've been talking about this step up in margins in the second half of the year relative to the first, and we've had a clear framework cycling through some of the headwinds in the first half of the year, like the higher cost inventory. That's behind us. We're seeing the benefits from the cost actions taken earlier in the year. We saw a partial impact in Q2. We saw a full quarter's impact in Q3. Then higher sales and getting some operating leverage from that. You can see that in our Q3 results. Hopefully a nice proof point to that kind of framework we've been talking about all year. As we think about Q4, our updated guidance implies a similar level of growth in Q4.

To your point, it's grown around 5% the last couple of quarters. We are expecting around that in Q4. When you think year-over-year, similar type drivers that we called out in Q3. Continued growth in our Infusion Therapies & Platforms portfolio, IV solutions growing off that new lower demand baseline, HST growing, Advanced Surgery and drug compounding, perhaps not at the same magnitude. They've been growing really well here lately, but expect continued growth in those businesses. I'd say a very consistent story as we look ahead to Q4 on a top-line perspective, and I would say it's the same story on operating margin as well. The implied Q4 operating margin contemplates a similar magnitude as what we saw in Q3. Do not expect any big call-outs sequentially Q3 to Q4.

Similar strength in the top line, similar mix, continued benefits from the cost actions, that should continue in Q4. I think the takeaway is Q4 should be another quarter that supports this framework that we laid out at the beginning of the year as far as improved performance. I believe the second part of your question was how do we think about that going forward. As John referenced, we're not giving FY 2027 guidance here today. We'll do that in February. But in general, I would just reiterate, we're predominantly in low single digit type markets. In FY 2026, we're performing a bit higher than that. It's clearly benefiting from some favorable comparisons. IV solutions, this new baseline, we're annualizing the impact of the Novum shipment and installation hold. Again, Advanced Surgery and drug compounding, their comps are going to get increasingly difficult going forward.

We've referenced some product exits are going to have some impact on the top line, but we will come back in February with a comprehensive view on what we expect 2027 to be. But right now, I'd say we're focused on the continued execution in Q4.

Understood. That's helpful, Kevin. John, one quick one for you. Thanks for laying out all the moving pieces and margins. By my math, between TSA, inflation, tariffs and ceph discontinuation, it almost feels like it's a couple of hundred basis points margin headwinds in 2027. Just curious on, are we thinking about margin headwinds for 2027, the right way, the magnitude of impact? Thank you.

Yeah, look, I set out in my response previously that there are clearly some margin headwinds. There are also some margin tailwinds, and we've got good visibility of cost-saving opportunities in the business. I've been very impressed, actually, with the level of detail and the rigor and the discipline that the organization is already deploying in driving efficiencies through the business. So, like in any situation, there are puts and takes, and that is the case for 2027. I'm not going to get drawn at the moment on what the net impact of those is going to be. We'll set that out in a little bit more detail in February. But as I said, look, there are clearly puts and takes.

I set out some of the headwinds, but equally, there are some tailwinds and some very good progress already made and a good pipeline developing of saving opportunities going into 2027.

Your next question from the line of Patrick Wood of UBS. Your question please.

Beautiful. Thanks, guys. Welcome, John. Two quick and dirty ones up front. The generic injectables business, obviously, there is a lot going on there in general. One of your peers also has a warning letter, as some of us remember what happened in the 20-teens with drug shortages. Given it is such a high margin business, general outlook there for you guys, obviously, one of your peers is going to be capacity constrained. Is there a tailwind from that, or are you restricted? Anything around there would be amazing for question one. Then just quickly, question two, sorry if I missed it. You mentioned the contract manufacturer effect. Any rough sizing of that and whether that situation has been resolved going forward? Sorry if I missed it.

Look, I will walk through a couple items first. By going to the non-ceph production, it really does allow us and enables us to simplify our operations. I mentioned a little bit earlier, but it supports greater supply resiliency. Therefore, by making this decision, and these are never easy decisions, it aligns well with really the future of that site, that organization, and we do view it gives us capability by reducing that complexity to continue to drive this product for our customer base in the non-ceph space. On the second piece of the question around the contract manufacturer, we have made good progress, and we are staying very close with this manufacturer to ensure that we are front and center on this production process and capability.

And so, while we are not giving an overall impact, what I can say is that we have made progress, and we are going to continue to keep this front and center to ensure this is something that we can work to mitigate over time.

Your next question from the line of Joanne Wuensch of Citi. Your question please.

Good morning. Thank you for taking the question, and John, welcome. Can we pause on the Advanced Surgery? I was just getting through the welcome to John part. Okay, here we go. Advanced Surgery. Double-digit growth on the quarter, nice acceleration. It does not appear to be an easy comp per se. What can we understand, what is driving that, the consistency of it, and anything to call out in terms of a one-time item in there to be aware of? Thank you.

Yeah. Look, let us start with the fundamentals. We are pleased with the progress, and this team has been really focused around driving execution in our core markets. Just as we piece this apart, the market is growing first, and that is a positive for our business and it is a strong growth area. But it is still in the call it single digits, call it low to mid-single digits. Number two, we have really aligned this team on how we can expand on a global scale. So we have seen some regions actually drive stronger growth on a global scale. Number three, and this is not a small piece. There has been a competitor that has had a challenge with supply. Because of our performance and our operation, we have been able to really maximize this impact.

I would say that is where it becomes a little bit of a challenge on a year-over-year comp perspective. That said, going back to the initial, we are pleased with the progress. This team is focused on finishing the year strong, getting ready for next year. As we think about the business into the future, certainly it is going to be year-over-year is going to be a more challenging comp, but the team is ready to continue to drive this business. We just view that the single piece of the supply challenge on a competitor is going to be something we are going to stay very close to.

Your next question from the line of Robert Marcus of JPMorgan. Your question please.

Hi, this is Lily on for Robbie. Thanks so much for taking the question. Following up on margins, I am hoping you can talk a bit more about what you are seeing on the macro side. You called out greater inflationary pressure in 2027. So what is the latest in terms of what you are seeing on cost pressures from oil, freight, et cetera, since you last updated us on the Q2 call, and what is baked into guidance in terms of pressures and your ability to offset them?

Yeah, I will pick that one up, Lily, and maybe Kevin will add to it. Look, as we have said, there are clearly inflationary pressures going into 2027, and arguably a slight step up that we have seen from 2026 due to the flow through of costs from inventory. But the key ones are actually, in order of impact, are things like salary inflation, the electronics and materials costs. Then distant third is things like utilities and energy and plastics and transportation and metals and packaging. So there are definitely inflationary costs coming through, and they are probably slightly more pronounced than they would ordinarily be. But that said, we have done a great job in 2026 of offsetting those with efficiency savings. We have got a good pipeline of savings programs going into 2027.

I have always operated with the philosophy of whatever inflationary pressures the business is facing, you have to look for an equal and opposite efficiency savings to neutralize those inflationary pressures. So that is certainly something that we will be aiming to do through 2027, but we will set this out in a lot more detail, of course, when we give our detailed guidance in February in terms of the puts and takes. But that is the way that we are thinking about it organizationally, if that helps.

Lily, just to add on a little bit to this. As a reminder, our exposure to fuel and oil is much less with the divestiture of our Kidney Care business. To John's point, we have taken a very proactive approach, and our teams are aligned around mitigating cost actions, driving engagement with suppliers, looking at efficiencies in the business. Overall, again, pleased with the progress. We have more work to do here.

Your next question from the line of Rick Wise with Stifel. Your question please.

Good morning. I think we cut off Lily there. Just to start, John, you highlighted your focus on improving cost structures. I was hoping you would expand on that comment, but also touch on the lower price contribution comment. I think I missed it. What was it, and how do we think about the impact of price, and thus on mix going forward?

Let me pick up on the question on cost structures, then I will hand over to Kevin to comment on price. I think on cost structures, as I said, there is already a tremendous amount of really good work going on in the business driving out cost, driving efficiencies, right across our business from our operations and supply chain to our functions. There is really, really, really good work in the detail. I have been incredibly impressed, actually, with the way that Baxter GPS is really being embedded into this business, and the discipline as to how we drive efficiency through the organizations is really coming to effect. That said, I did highlight in my opening remarks that there remains a lot of complexity in this organization. There remains a lot of processes that are not standardized. It is not unusual.

In fact, pretty much every business I have ever come into, of course of our scale and size, naturally has this embedded complexity and has perhaps not standardized processes as much as it can. If you look at the headline level at some of our functions, for example, like IT, we have got an incredible number of applications that we run in our business. There is definitely opportunity there to simplify and standardize. Again, even with our finance function, if you look at our overall cost base across finance and across IT, if you benchmark that, it definitely shows opportunities to drive out more efficiencies going forward.

One of the key things I said that I am going to be focused on is how do we continue the great work that is already underway, but build a very much sustainable pipeline of efficiency savings, not just in the next 12 months, but looking forward over the next three years. I believe it is early days yet. I have been in the organization for three weeks, but I believe there is the opportunity to do that.

Rick, with respect to pricing, the commentary was, when you think about operating income dollars year-over-year, there was less contribution from pricing, and it is really a prior year story. If you recall last year, we saw the benefit from two of our GPO renewals. This mostly impacted the MPT segment. This year, it is really kind of the absence of that outsized benefit when you think about the year-over-year. This was an expected headwind when we entered the year. We called it out last quarter and we again saw that in Q3.

Just as a follow-up question. Infusion systems obviously contributed to growth this quarter. Injectables, as we have heard, remained a drag. How much of the pump improvement reflects the Spectrum demand versus easier comps, perhaps? What is going on there, and what milestones remain now before Novum LVP can get to market? Thank you.

Yeah. I guess I will kind of work backwards on this. We are continuing to make good progress with Novum LVP, and we are working closely with the regulatory authorities in this process, and when there is an update, we will certainly provide it. As far as our pump portfolio, with our Spectrum LVP, as well as our Novum syringe, now it is communicating through our IQX software platform. We have continued to evolve and really align around innovation in the space with PureView as well as other areas. We are feeling good about our offerings and our value proposition. Even earlier this week, I had a chance to sit down with a customer and walk through our pump portfolio, where it sits in their ability to drive high care, how they look at efficiencies, and our ability to support that. We are pleased with where we sit.

Again, we have got opportunity for the future, and we are going to continue to focus on making progress.

Your next question from the line of Jayson Bedford of Raymond James & Associates. Your question please.

Good morning and congrats on the progress. I do not mean to put you on the spot with this question, but one of your medtech peers announced an agreement with the administration to onshore production in exchange for tariff relief. I am just wondering, is this something you are looking into?

Yeah. So good morning, and as far as tariffs go, we continue to look at opportunities that we can, I would say, maximize or minimize the impact. We have certainly opportunities. We saw this year a bit of a benefit here. We are going to continue to look at that as an opportunity, and as you know, we have got a strong footprint in the U.S., and we have got strong demand in the U.S. No headline discussion as of now. That said, we are continuing to look at areas that we can minimize overall tariff impact on the business.

Okay, thanks. Just maybe as a quick follow-up, is there any way to frame the impact of the supply chain challenges in the pharma business this year? It sounds like it is getting better, but specifically, I am wondering how much of an offset it could be relative to the discontinuation of the ceph products.

Yeah. So we are not outlining that in totality. That said, you are picking up on one of the areas of focus is certainly with our ceph business and that product set going away. And it was a conscious, proactive decision of discontinuing that product. There are offsets that we are looking at. One of them is the continued support of the product that we talked about with the contract manufacturer. There is also other products that we are enabling and working with customers on within that space that will support the ability for them to have the capability in their patient care, site of care. And so while we are not outlining the offsets today, we are going to continue to show that as we go into next year.

There are no further questions at this time. I will now turn the call back to Mr. Hider for closing remarks.

Thanks, operator, and thank you for your questions today. As I have shared, we are encouraged by the progress we are making. While we have more work ahead, execution is improving. We are delivering against our priorities, and we are building a stronger Baxter. Thank you and have a great day.

Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.

Baxter International (BAX) Q3 2026 Earnings Call Transcript

Company Participants